MELISI, Davide
MELISI, Davide
DIPARTIMENTO DI MEDICINA
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
2017-01-01 Humphries, Matthew P; Sundara Rajan, Sreekumar; Droop, Alastair; Suleman, Charlotte A. B; Carbone, Carmine; Nilsson, Cecilia; Honarpisheh, Hedieh; Cserni, Gabor; Dent, Jo; Fulford, Laura; Jordan, Lee B; Jones, J. Louise; Kanthan, Rani; Litwiniuk, Maria; Di Benedetto, Anna; Mottolese, Marcella; Provenzano, Elena; Shousha, Sami; Stephens, Mark; Walker, Rosemary A; Kulka, Janina; Ellis, Ian O; Jeffery, Margaret; Thygesen, Helene H; Cappelletti, Vera; Daidone, Maria G; Hedenfalk, Ingrid A; Fjällskog, Marie Louise; Melisi, Davide; Stead, Lucy F; Shaaban, Abeer M; Speirs, Valerie
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
2017-01-01 Piro, Geny; Simionato, Francesca; Carbone, Carmine; Frizziero, Melissa; Malleo, Giuseppe; Zanini, SILVIA MARIA; Casolino, Raffaella; Santoro, Raffaela; Mina, Maria Mihaela; Zecchetto, Camilla; Merz, Valeria; Scarpa, Aldo; Bassi, Claudio; Tortora, Giampaolo; Melisi, Davide
A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
2021-01-01 Pietrobono, Silvia; Melisi, Davide
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts
2005-01-01 Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V.
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts.
2005-01-01 Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V.
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
2020-01-01 Simionato, F; Zecchetto, C; Merz, V; Cavaliere, A; Casalino, S; Gaule, M; D'Onofrio, M; Malleo, G; Landoni, L; Esposito, A; Marchegiani, G; Casetti, L; Tuveri, M; Paiella, S; Scopelliti, F; Giardino, A; Frigerio, I; Regi, P; Capelli, P; Gobbo, S; Gabbrielli, A; Bernardoni, L; Fedele, V; Rossi, I; Piazzola, C; Giacomazzi, S; Pasquato, M; Gianfortone, M; Milleri, S; Milella, M; Butturini, G; Salvia, R; Bassi, C; Melisi, D
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
2020-01-01 Merz, Valeria; Zecchetto, Camilla; Simionato, Francesca; Cavaliere, Alessandro; Casalino, Simona; Pavarana, Michele; Giacopuzzi, Simone; Bencivenga, Maria; Tomezzoli, Anna; Santoro, Raffaela; Fedele, Vita; Contarelli, Serena; Rossi, Irene; Giacomazzi, Serena; Pasquato, Martina; Piazzola, Cristiana; Milleri, Stefano; de Manzoni, Giovanni; Melisi, Davide
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024-01-01 Niger, Monica; Nichetti, Federico; Fornaro, Lorenzo; Pircher, Chiara; Morano, Federica; Palermo, Federica; Rimassa, Lorenza; Pressiani, Tiziana; Berardi, Rossana; Gardini, Andrea Casadei; Sperti, Elisa; Salvatore, Lisa; Melisi, Davide; Bergamo, Francesca; Siena, Salvatore; Mosconi, Stefania; Longarini, Raffaella; Arcangeli, Giuseppina; Corallo, Salvatore; Delliponti, Laura; Tamberi, Stefano; Fea, Elena; Brandi, Giovanni; Rapposelli, Ilario Giovanni; Salati, Massimiliano; Baili, Paolo; Miceli, Rosalba; Ljevar, Silva; Cavallo, Ilaria; Sottotetti, Elisa; Martinetti, Antonia; Busset, Michele Droz Dit; Sposito, Carlo; Di Bartolomeo, Maria; Pietrantonio, Filippo; de Braud, Filippo; Mazzaferro, Vincenzo
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration
2002-01-01 Tortora, Giampaolo; Caputo, R.; Damiano, V.; Melisi, Davide; Bianco, R.; Fontanini, G.; Bianco, A. R.; Ciardiello, F.
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling
2018-01-01 Carbone, C; Piro, G; Gaianigo, Nicola; Ligorio, F; Santoro, R; Merz, V; Simionato, F; Zecchetto, C; Falco, G; Conti, G; Kamga, P. T; Krampera, M; Di Nicolantonio, F; De Franceschi, L; Scarpa, A; Tortora, G; Melisi, D.
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data
2019-01-01 Marchegiani, Giovanni; Andrianello, Stefano; Dal Borgo, Chiara; Secchettin, Erica; Melisi, Davide; Malleo, Giuseppe; Bassi, Claudio; Salvia, Roberto
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE
2005-01-01 Tortora, Giampaolo; Melisi, Davide
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis
2015-01-01 Carbone, C; Piro, G; Fassan, Matteo; Tamburrino, A; Mina, Maria Mihaela; Zanotto, M; Chiao, Pj; Bassi, Claudio; Scarpa, Aldo; Tortora, Giampaolo; Melisi, Davide
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients
2016-01-01 Piro, Geny; Carbone, Carmine; Cataldo, Ivana; Di Nicolantonio, Federica; Giacopuzzi, Simone; Aprile, Giuseppe; Simionato, Francesca; Boschi, Federico; Zanotto, Marco; Mina, Maria Mihaela; Santoro, Raffaela; Merz, Valeria; Sbarbati, Andrea; DE MANZONI, Giovanni; Scarpa, Aldo; Tortora, Giampaolo; Melisi, Davide
Angiogenesis: A target for cancer therapy.
2004-01-01 Tortora, Giampaolo; Melisi, Davide; Ciardiello, F.
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
2018-01-01 Carbone, Carmine; Piro, Geny; Merz, Valeria; Simionato, Francesca; Santoro, Raffaela; Zecchetto, Camilla; Tortora, Giampaolo; Melisi, Davide
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype
2011-01-01 Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, Davide
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
2011-01-01 Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, Davide
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
2004-01-01 Raben, D; Bianco, C; Damiano, V; Bianco, R; Melisi, Davide; Mignogna, C; Darmiento, Fp; Cionini, L; Bianco, Ar; Tortora, Giampaolo; Ciardiello, F; Bunn, P.
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
2004-01-01 D., Raben; C., Bianco; V., Damiano; R., Bianco; Melisi, Davide; C., Mignogna; F. P., D'Armiento; L., Cionini; A. R., Bianco; Tortora, Giampaolo; F., Ciardiello; P., Bunn
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer | 1-gen-2017 | Humphries, Matthew P; Sundara Rajan, Sreekumar; Droop, Alastair; Suleman, Charlotte A. B; Carbone, Carmine; Nilsson, Cecilia; Honarpisheh, Hedieh; Cserni, Gabor; Dent, Jo; Fulford, Laura; Jordan, Lee B; Jones, J. Louise; Kanthan, Rani; Litwiniuk, Maria; Di Benedetto, Anna; Mottolese, Marcella; Provenzano, Elena; Shousha, Sami; Stephens, Mark; Walker, Rosemary A; Kulka, Janina; Ellis, Ian O; Jeffery, Margaret; Thygesen, Helene H; Cappelletti, Vera; Daidone, Maria G; Hedenfalk, Ingrid A; Fjällskog, Marie Louise; Melisi, Davide; Stead, Lucy F; Shaaban, Abeer M; Speirs, Valerie | |
| A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma | 1-gen-2017 | Piro, Geny; Simionato, Francesca; Carbone, Carmine; Frizziero, Melissa; Malleo, Giuseppe; Zanini, SILVIA MARIA; Casolino, Raffaella; Santoro, Raffaela; Mina, Maria Mihaela; Zecchetto, Camilla; Merz, Valeria; Scarpa, Aldo; Bassi, Claudio; Tortora, Giampaolo; Melisi, Davide | |
| A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib | 1-gen-2021 | Pietrobono, Silvia; Melisi, Davide | |
| A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts | 1-gen-2005 | Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V. | |
| A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. | 1-gen-2005 | Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V. | |
| A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial | 1-gen-2020 | Simionato, F; Zecchetto, C; Merz, V; Cavaliere, A; Casalino, S; Gaule, M; D'Onofrio, M; Malleo, G; Landoni, L; Esposito, A; Marchegiani, G; Casetti, L; Tuveri, M; Paiella, S; Scopelliti, F; Giardino, A; Frigerio, I; Regi, P; Capelli, P; Gobbo, S; Gabbrielli, A; Bernardoni, L; Fedele, V; Rossi, I; Piazzola, C; Giacomazzi, S; Pasquato, M; Gianfortone, M; Milleri, S; Milella, M; Butturini, G; Salvia, R; Bassi, C; Melisi, D | |
| A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial | 1-gen-2020 | Merz, Valeria; Zecchetto, Camilla; Simionato, Francesca; Cavaliere, Alessandro; Casalino, Simona; Pavarana, Michele; Giacopuzzi, Simone; Bencivenga, Maria; Tomezzoli, Anna; Santoro, Raffaela; Fedele, Vita; Contarelli, Serena; Rossi, Irene; Giacomazzi, Serena; Pasquato, Martina; Piazzola, Cristiana; Milleri, Stefano; de Manzoni, Giovanni; Melisi, Davide | |
| A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study | 1-gen-2024 | Niger, Monica; Nichetti, Federico; Fornaro, Lorenzo; Pircher, Chiara; Morano, Federica; Palermo, Federica; Rimassa, Lorenza; Pressiani, Tiziana; Berardi, Rossana; Gardini, Andrea Casadei; Sperti, Elisa; Salvatore, Lisa; Melisi, Davide; Bergamo, Francesca; Siena, Salvatore; Mosconi, Stefania; Longarini, Raffaella; Arcangeli, Giuseppina; Corallo, Salvatore; Delliponti, Laura; Tamberi, Stefano; Fea, Elena; Brandi, Giovanni; Rapposelli, Ilario Giovanni; Salati, Massimiliano; Baili, Paolo; Miceli, Rosalba; Ljevar, Silva; Cavallo, Ilaria; Sottotetti, Elisa; Martinetti, Antonia; Busset, Michele Droz Dit; Sposito, Carlo; Di Bartolomeo, Maria; Pietrantonio, Filippo; de Braud, Filippo; Mazzaferro, Vincenzo | |
| A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration | 1-gen-2002 | Tortora, Giampaolo; Caputo, R.; Damiano, V.; Melisi, Davide; Bianco, R.; Fontanini, G.; Bianco, A. R.; Ciardiello, F. | |
| Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling | 1-gen-2018 | Carbone, C; Piro, G; Gaianigo, Nicola; Ligorio, F; Santoro, R; Merz, V; Simionato, F; Zecchetto, C; Falco, G; Conti, G; Kamga, P. T; Krampera, M; Di Nicolantonio, F; De Franceschi, L; Scarpa, A; Tortora, G; Melisi, D. | |
| Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data | 1-gen-2019 | Marchegiani, Giovanni; Andrianello, Stefano; Dal Borgo, Chiara; Secchettin, Erica; Melisi, Davide; Malleo, Giuseppe; Bassi, Claudio; Salvia, Roberto | |
| AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE | 1-gen-2005 | Tortora, Giampaolo; Melisi, Davide | |
| An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis | 1-gen-2015 | Carbone, C; Piro, G; Fassan, Matteo; Tamburrino, A; Mina, Maria Mihaela; Zanotto, M; Chiao, Pj; Bassi, Claudio; Scarpa, Aldo; Tortora, Giampaolo; Melisi, Davide | |
| An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients | 1-gen-2016 | Piro, Geny; Carbone, Carmine; Cataldo, Ivana; Di Nicolantonio, Federica; Giacopuzzi, Simone; Aprile, Giuseppe; Simionato, Francesca; Boschi, Federico; Zanotto, Marco; Mina, Maria Mihaela; Santoro, Raffaela; Merz, Valeria; Sbarbati, Andrea; DE MANZONI, Giovanni; Scarpa, Aldo; Tortora, Giampaolo; Melisi, Davide | |
| Angiogenesis: A target for cancer therapy. | 1-gen-2004 | Tortora, Giampaolo; Melisi, Davide; Ciardiello, F. | |
| Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer | 1-gen-2018 | Carbone, Carmine; Piro, Geny; Merz, Valeria; Simionato, Francesca; Santoro, Raffaela; Zecchetto, Camilla; Tortora, Giampaolo; Melisi, Davide | |
| Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype | 1-gen-2011 | Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, Davide | |
| Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. | 1-gen-2011 | Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, Davide | |
| Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. | 1-gen-2004 | Raben, D; Bianco, C; Damiano, V; Bianco, R; Melisi, Davide; Mignogna, C; Darmiento, Fp; Cionini, L; Bianco, Ar; Tortora, Giampaolo; Ciardiello, F; Bunn, P. | |
| Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. | 1-gen-2004 | D., Raben; C., Bianco; V., Damiano; R., Bianco; Melisi, Davide; C., Mignogna; F. P., D'Armiento; L., Cionini; A. R., Bianco; Tortora, Giampaolo; F., Ciardiello; P., Bunn |